HOTH Valuation

Hoth Therapeutics Inc

Add to Watchlist

Advanced Chart

1.920

+0.175(10.029%)1D

Overview
Forecast
Valuation
Earnings

HOTH Relative Valuation

HOTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HOTH is overvalued; if below, it's undervalued.

Historical Valuation

Hoth Therapeutics Inc (HOTH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.69. The fair price of Hoth Therapeutics Inc (HOTH) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.75

Fair

-3.42

Trailing

Forward

0.00

EV/EBITDA

Hoth Therapeutics Inc. (HOTH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.16. The thresholds are as follows: Strongly Undervalued below -6.83, Undervalued between -6.83 and -3.50, Fairly Valued between 3.18 and -3.50, Overvalued between 3.18 and 6.52, and Strongly Overvalued above 6.52. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.03

EV/EBIT

Hoth Therapeutics Inc. (HOTH) has a current EV/EBIT of -1.03. The 5-year average EV/EBIT is -0.38. The thresholds are as follows: Strongly Undervalued below -2.70, Undervalued between -2.70 and -1.54, Fairly Valued between 0.78 and -1.54, Overvalued between 0.78 and 1.93, and Strongly Overvalued above 1.93. The current Forward EV/EBIT of -1.03 falls within the Historic Trend Line -Fairly Valued range.

0.00

Hoth Therapeutics Inc. (HOTH) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Hoth Therapeutics Inc. (HOTH) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.24. The thresholds are as follows: Strongly Undervalued below -3.98, Undervalued between -3.98 and -2.61, Fairly Valued between 0.12 and -2.61, Overvalued between 0.12 and 1.49, and Strongly Overvalued above 1.49. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Hoth Therapeutics Inc. (HOTH) has a current P/FCF of 0.00. The 5-year average P/FCF is 155.72. The thresholds are as follows: Strongly Undervalued below -1209.71, Undervalued between -1209.71 and -526.99, Fairly Valued between 838.44 and -526.99, Overvalued between 838.44 and 1521.15, and Strongly Overvalued above 1521.15. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Hoth Therapeutics Inc (HOTH) has a current Price-to-Book (P/B) ratio of 2.37. Compared to its 3-year average P/B ratio of 0.84 , the current P/B ratio is approximately 182.40% higher. Relative to its 5-year average P/B ratio of 1.56, the current P/B ratio is about 52.38% higher. Hoth Therapeutics Inc (HOTH) has a Forward Free Cash Flow (FCF) yield of approximately -36.36%. Compared to its 3-year average FCF yield of -134.04%, the current FCF yield is approximately -72.87% lower. Relative to its 5-year average FCF yield of -98.22% , the current FCF yield is about -62.98% lower.

2.37

P/B

Median3y

0.84

Median5y

1.56

-36.36

FCF Yield

Median3y

-134.04

Median5y

-98.22

Competitors Valuation Multiple

The average P/S ratio for HOTH's competitors is 402.67, providing a benchmark for relative valuation. Hoth Therapeutics Inc Corp (HOTH) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HOTH.O

Hoth Therapeutics Inc

Lisata Therapeutics Inc

711.61

20.40M

LEXX.O

Lexaria Bioscience Corp

Performance Decomposition

Market capitalization of HOTH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of HOTH in the past 1 year is driven by Unknown.